CJC-1295 / Ipamorelin Blend

CJC-1295 (No DAC) and Ipamorelin are two peptides commonly studied together for their complementary effects on growth-hormone–related pathways.
CJC-1295 is an analog of Growth Hormone–Releasing Hormone (GHRH) and is designed to stimulate the pituitary through GHRH receptors. Ipamorelin, a selective Growth Hormone Secretagogue, acts on a separate receptor family to promote growth-hormone release through a ghrelin-mediated pathway.

By engaging two distinct receptor systems, the CJC-1295/Ipamorelin combination is investigated for its potential to enhance pulsatile growth hormone output and influence downstream signaling pathways tied to cellular repair, metabolism, and tissue homeostasis.

Research exploring this peptide combination has examined potential effects in areas such as musculoskeletal health, metabolic function, neural support, and general tissue regeneration. Studies continue to investigate how these peptides may influence bone density pathways, lean tissue development, fat-metabolism signaling, immune modulation, and recovery mechanisms.

Overall, the CJC-1295 (No DAC) / Ipamorelin blend remains a subject of significant scientific interest for its dual-pathway activation and its broad relevance across endocrine and regenerative research.

Disclaimer: This peptide is for research and educational purposes only. It is not intended for diagnostic or therapeutic use without the guidance of a qualified healthcare professional.